Format

Send to:

Choose Destination
See comment in PubMed Commons below
PLoS Med. 2005 Feb;2(2):e38. Epub 2005 Feb 22.

Use of procalcitonin and C-reactive protein to evaluate vaccine efficacy against pneumonia.

Author information

  • 1National Health Laboratory Service, University of The Witwatersrand, Johannesburg, South Africa. madhis@hivsa.com

Abstract

BACKGROUND:

Pneumonia remains the leading cause of death in young children. The poor specificity of chest radiographs (CXRs) to diagnose pneumococcal pneumonia may underestimate the efficacy of pneumococcal conjugate vaccine in preventing pneumococcal pneumonia.

METHODS AND FINDINGS:

The efficacy of nine-valent pneumococcal conjugate vaccine among children not infected with HIV (21%; 95% confidence interval, 1%-37%) increased when CXR-confirmed pneumonia was associated with serum C-reactive protein of 120 mg/l (12 mg/dl) or more and procalcitonin of 5.0 ng/ml or more (64%; 95% confidence interval, 23%-83%). Similar results were observed in children infected with HIV.

CONCLUSION:

C-reactive protein and procalcitonin improve the specificity of CXR to diagnose pneumococcal pneumonia and may be useful for the future evaluation of the effectiveness of pneumococcal conjugate vaccine in preventing pneumococcal pneumonia.

PMID:
15736995
[PubMed - indexed for MEDLINE]
PMCID:
PMC549587
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Public Library of Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk